Led by $880.85m asset transaction with Novasep Holding, Europe’s medical devices industry saw a drop of 8.95% in deal activity during Q1 2021, when compared to the last four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

 

A total of 89 deals worth $2.99bn were announced for the region during Q1 2021, against the last four-quarter average of 97.75 deals.

Of all the deal types, venture financing saw most activity in Q1 2021 with 46 deals, representing a 51.7% share for the region.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

In second place was M&A with 36 deals, followed by private equity deals with seven transactions, respectively capturing a 40.5% and 7.9% share of the overall deal activity for the quarter.

In terms of value of deals, M&A was the leading category in Europe’s medical devices industry with $2.38bn, while venture financing and private equity deals totalled $391.2m and $228m, respectively.

Europe medical devices industry deals in Q1 2021: Top deals

The top five medical devices deals accounted for a 71.8% share of the overall value during Q1 2021.

The combined value of the top five deals stood at $2.15bn, against the overall value of $2.99bn recorded for the quarter.

The top five medical devices industry deals of Q1 2021 tracked by GlobalData were:

1) Thermo Fisher Scientific’s $880.85m asset transaction with Novasep Holding

2) The $591m acquisition of Oxford Immunotec by PerkinElmer

3) Savaria’s $409.7m acquisition of Handicare Group

4) The $159m acquisition deal with Diagenode by Hologic

5) Sino Biopharmaceutical’s venture financing with Softhale for $110m.